SINT Sintx Technologies, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1269026 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY160.8%
TTM net income YoY5.2%
TTM EPS YoY13.0%
Revenue 3-yr CAGR10.0%
Net income 3-yr CAGR—
Margins
Gross margin59.5%
Operating margin-303.4%
Net margin-281.9%
FCF margin-279.2%
EBITDA margin-295.3%
Returns
ROE-250.4%
ROA-92.1%
ROIC (approx.)—
Asset turnover0.33x
Leverage & solvency
Liabilities / assets61.9%
Debt / equity0.00x
Current ratio1.84x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.96x
Accruals ratio-3.6%
Payout ratio—
Capex / revenue8.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.02M | $2.89M |
| Cost of revenue | $557,000 | $811,000 |
| Gross profit | $461,000 | $2.08M |
| R&D expense | $4.59M | $5.20M |
| SG&A expense | $6.20M | $4.00M |
| Operating income | -$10.72M | -$14.05M |
| Pretax income | -$10.36M | -$11.02M |
| Net income | -$10.36M | -$11.02M |
| EBITDA | -$10.40M | -$13.21M |
| EPS (basic) | -6.16 | -14.87 |
| EPS (diluted) | -6.16 | -15.19 |
| Weighted avg. shares (diluted) | 2.77M | 744,782 |
| Balance sheet | ||
| Cash & equivalents | $4.14M | $3.60M |
| Inventory | $825,000 | $502,000 |
| Current assets | $5.65M | $4.52M |
| PP&E, net | $476,000 | $922,000 |
| Goodwill | $302,000 | — |
| Intangibles | $142,000 | $16,000 |
| Total assets | $9.51M | $9.41M |
| Current liabilities | $3.73M | $1.98M |
| Short-term debt | $7,000 | $32,000 |
| Total liabilities | $6.58M | $5.52M |
| Shareholders' equity | $2.93M | $3.89M |
| Shares outstanding | 3.97M | 1.34M |
| Cash flow statement | ||
| Operating cash flow | -$8.57M | -$8.64M |
| Capital expenditure | $185,000 | $690,000 |
| Free cash flow | -$8.76M | -$9.33M |
| Investing cash flow | $913,000 | -$194,000 |
| Financing cash flow | $8.20M | $9.09M |
| Depreciation & amortization | $319,000 | $842,000 |
| Stock-based compensation | $1.39M | $82,000 |
| Share buybacks | $133,000 | — |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.